Future research should focus on developing EGFRvIII-targeting approaches, including mRNA vaccines and LCN2/STAT3 inhibitors, while exploring combination therapies that simultaneously address tumor-intrinsic and TME-mediated mechanisms. This evidence concerns the gene STAT3 and neoplasm.